Centric Wealth Management Buys New Position in Molina Healthcare, Inc $MOH

Centric Wealth Management bought a new stake in Molina Healthcare, Inc (NYSE:MOH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,798 shares of the company’s stock, valued at approximately $547,000.

A number of other large investors have also recently bought and sold shares of MOH. Torren Management LLC bought a new stake in shares of Molina Healthcare in the fourth quarter worth $26,000. Physician Wealth Advisors Inc. grew its position in Molina Healthcare by 1,250.0% in the first quarter. Physician Wealth Advisors Inc. now owns 216 shares of the company’s stock valued at $29,000 after purchasing an additional 200 shares in the last quarter. Quarry LP acquired a new stake in Molina Healthcare in the 4th quarter valued at $32,000. Triumph Capital Management increased its stake in Molina Healthcare by 4,625.0% in the 4th quarter. Triumph Capital Management now owns 189 shares of the company’s stock valued at $33,000 after buying an additional 185 shares during the last quarter. Finally, SJS Investment Consulting Inc. lifted its position in Molina Healthcare by 504.9% during the 1st quarter. SJS Investment Consulting Inc. now owns 248 shares of the company’s stock worth $33,000 after buying an additional 207 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MOH shares. Bank of America upgraded shares of Molina Healthcare from an “underperform” rating to a “buy” rating and set a $250.00 price objective for the company in a research note on Wednesday, April 29th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Molina Healthcare in a report on Friday, July 24th. Truist Financial reduced their price target on Molina Healthcare from $250.00 to $225.00 and set a “hold” rating for the company in a research report on Friday, July 24th. Sanford C. Bernstein set a $286.00 price target on Molina Healthcare in a research note on Monday, July 13th. Finally, UBS Group boosted their price target on Molina Healthcare from $180.00 to $202.00 and gave the stock a “neutral” rating in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $202.44.

Key Headlines Impacting Molina Healthcare

Here are the key news stories impacting Molina Healthcare this week:

• Positive Sentiment: Zacks Research raised multiple future EPS forecasts and reiterated a “Strong-Buy” rating. Estimates increased for Q4 2026 to $0.70 from $0.53, Q1 2027 to $2.53 from $1.60, Q2 2027 to $2.22 from $1.82, Q4 2027 to $2.87 from $2.00, FY2027 to $10.05 from $7.61, and FY2028 to $11.94 from $9.76. The revisions suggest analysts see stronger earnings power beyond the near term, although the current-year consensus remains $5.29 per share.
• Positive Sentiment: Recent quarterly results and raised guidance are supporting a recovery in sentiment. Molina reported second-quarter adjusted EPS of $1.51, above expectations, and increased its minimum 2026 adjusted earnings outlook to $5.25 from $5.00. Investors appear to be reassessing the stock after its post-earnings selloff, with Medicaid policy clarity and resilient profitability helping drive the rebound. Molina Healthcare Surged on Medicaid Clarity and Robust Results
• Positive Sentiment: Investor interest from Michael Burry provides an additional sentiment boost. Burry reportedly added to his Molina position at approximately $198, signaling confidence in the company’s valuation and longer-term healthcare prospects ahead of election-related Medicaid policy discussions. Michael Burry Adds to Molina Healthcare Position
• Neutral Sentiment: Not all estimate changes were favorable. Zacks reduced its Q3 2026 EPS forecast to $0.72 from $1.07 and cut Q2 2028 EPS to $2.30 from $2.60, underscoring continuing near-term earnings and cost pressures.
• Negative Sentiment: Insider transactions were weighted toward selling. Company insiders recorded three sales versus one purchase over the past six months, a potentially cautious signal, though these transactions do not necessarily reflect management’s outlook.

Molina Healthcare Stock Up 3.2%

Molina Healthcare stock opened at $212.24 on Friday. The firm has a market capitalization of $11.08 billion, a PE ratio of -1,179.07, a P/E/G ratio of 30.44 and a beta of 0.75. The company’s 50-day moving average is $210.98 and its 200-day moving average is $178.08. Molina Healthcare, Inc has a fifty-two week low of $121.06 and a fifty-two week high of $244.89. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.68 and a quick ratio of 1.68.

Molina Healthcare (NYSE:MOH) last issued its earnings results on Wednesday, July 22nd. The company reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.12. Molina Healthcare had a negative net margin of 0.02% and a positive return on equity of 3.73%. The company had revenue of $10.87 billion for the quarter, compared to analysts’ expectations of $10.83 billion. During the same period in the prior year, the firm earned $5.48 EPS. Molina Healthcare’s quarterly revenue was down 4.8% compared to the same quarter last year. Sell-side analysts anticipate that Molina Healthcare, Inc will post 5.29 earnings per share for the current year.

About Molina Healthcare

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.